Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation) on November 14, 2018. The report details significant corporate governance changes and a legal name change effective November 19, 2018.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive appointments and corporate restructuring.
Material Changes
- Executive Leadership: Gerrit Dispersyn, Dr. Med. Sc., was appointed President and Chief Operating Officer (COO) effective November 14, 2018. He previously served as Chief Development Officer since April 2017.
- Role Transition: Geert Cauwenbergh, Dr. Med. Sc., ceased his role as President effective November 14, 2018, but continues to serve as Chief Executive Officer (CEO) and principal executive and financial officer.
- Corporate Name Change: The company legally changed its name from RXi Pharmaceuticals Corporation to Phio Pharmaceuticals Corp. effective November 19, 2018.
- Trading Symbols: Common stock and listed warrants began trading on The Nasdaq Capital Market under the new ticker symbols "PHIO" and "PHIOW," respectively, on November 19, 2018.
Management Commentary, Risks, and Unusual Items
Compensation and Severance for New COO:
- Dr. Dispersyn's current base salary is $320,000, with a performance bonus of up to 30% of base salary.
- Equity Grants: He holds options for 9,500 shares (granted April 2017, vesting monthly over 4 years) and 16,000 shares (granted August 2018, vesting annually over 4 years), plus 16,000 restricted stock units (vesting annually over 4 years).
- Severance Provisions:
- Termination without "cause" or for "good reason": 6 months of salary plus continued medical/dental benefits.
- Termination within 12 months of a "change of control": 12 months of salary, accelerated vesting of 50% of unvested options (or the portion vesting over the next 24 months, whichever is greater), and continued medical/dental benefits.
Corporate Governance: The company adopted Amended and Restated Bylaws solely to reflect the name change. No other changes were made to the Certificate of Incorporation.
Investor Verification Checklist
- Verify the new ticker symbols "PHIO" and "PHIOW" on The Nasdaq Capital Market.
- Confirm the effective date of the name change (November 19, 2018) for legal and trading records.
- Review the full text of Dr. Dispersyn's Employment Agreement (Exhibit 10.22 referenced in prior filings) for detailed definitions of "cause" and "good reason."
- Monitor future filings for the impact of the leadership transition on clinical development strategies.